盐酸埃克替尼治疗表皮生长因子受体突变的晚期非小细胞肺癌的疗效观察  

Curative Effect Observation of Icotinib in the Treatment of Patients with Advanced Non- small Cell Lung Cancer and Epidermal Growth Factor Receptor( EGFR) Mutations

作　　者：苏晓妹[1] 刘桢[1] 朱亚杰[1] 刘焕义[1] 赵振国[1] 张涛[1] 

机构地区：[1]中国人民解放军成都军区总医院肿瘤诊治中心,四川省成都市610083

出　　处：《中国全科医学》2013年第33期3967-3969,共3页Chinese General Practice

摘　　要：目的观察盐酸埃克替尼治疗表皮生长因子受体(EGFR)突变的非小细胞肺癌(NSCLC)患者的疗效、无疾病进展生存期(PFS)及不良反应。方法选取2011年10月—2012年4月我院收治的EGFR突变的晚期NSCLC患者38例,化疗失败后口服盐酸埃克替尼125 mg/次,3次/d,评价近期疗效、PFS及不良反应。结果接受盐酸埃克替尼治疗的38例患者中,1例达到完全缓解(CR),服药3个月后1例出现进展(PD)。38例患者中位PFS为10个月〔95%CI(8.91,11.09)〕。女性患者的中位PFS为10个月〔95%CI(8.34,11.66)〕,男性患者的中位PFS为6个月〔95%CI(1.20,10.80)〕,差异有统计学意义(P=0.01)。Cox多因素分析显示,性别、吸烟、病理类型、年龄、功能状态评分(PS评分)、分期、既往化疗史、有无皮疹与PFS均无相关性。不良反应有皮疹24例(63.2%),腹泻11例(28.9%),无一例因不良反应停药。结论盐酸埃克替尼治疗EGFR突变的晚期NSCLC疗效肯定,不良反应少且轻微,可耐受,安全性好。Objective To observe curative effect, progression -free survival （PFS） and adverse reaction of icotinib in the treatment of patients with advanced non - small cell lung cancer （NSCLC） and epidermal growth factor receptor （EGFR） mutations. Methods From October 2011 to April 2012, 38 patients with advanced NSCLC and EGFR mutations were admitted to our hospital, when their chemotherapy failed, these patients were treated with icotinib 125rag by mouth thred times a day, then the short -term curative effect, PFS and adverse reaction were evaluated. Results Among the 38 patients who received icotinib therapy, 1 case had a complete response, and 1 case had progressive disease after 3 months. Median progression -free survival for 38 patients was 10 months [95%CI （8. 91, 11.09） ] . Median progression -free survival for female patients was 10 months 95 % CI （ 8. 34, 11.66）], and median progression - free survival for male patients was 6 months [ 95% CI （ 1.20, 10. 80） ], the difference was statistically significant （P =0. O1 ） . Multivariable analysis of Cox model showed that PFS had no correlation with sex, smoking status, pathological type, age, performance status score, clinical stage, history of chemotherapy and the presence of skin rash. The most common adverse reactions were skin rashes （24 patients, 63.2% ） and diarrhea （ 11 patients, 28.9% ）, no patien stopped treatment because of adverse reactions. Conclusion The curative effect of icotinib in the treatment of patients with advanced NSCLC and EGFR mutations is satisfactory, few patients have adverse reaction, and the extent of ad- verse reaction is light, therapy with ieotinib is safety, the patients can tolerate therapy with icotinib.

关 键 词：癌 非小细胞肺 受体 表皮生长因子 盐酸埃克替尼 治疗结果 

分 类 号：R734.2[医药卫生—肿瘤]